Radical -xh Acid, Or Anhydride, Acid Halide Or Salt Thereof (x Is Chalcogen) Doai Patents (Class 514/553)
  • Patent number: 9827197
    Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
    Type: Grant
    Filed: November 6, 2014
    Date of Patent: November 28, 2017
    Assignee: APR APPLIED PHARMA RESEARCH SA
    Inventors: Giorgio Reiner, Alberto Reiner, Andreas Meyer
  • Patent number: 9723833
    Abstract: The present invention provides a biocide composition comprising a biocide and a carrier, wherein the biocide is soluble in the carrier. The carrier may comprise polyethylene glycol ester. The present invention also provides a method for controlling biofilms by eliminating and/or preventing microorganisms in an aqueous environment.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: August 8, 2017
    Assignee: KEMIRA OYJ
    Inventors: Marko Kolari, Jukka Rautiainen
  • Patent number: 9648875
    Abstract: Formulations and wipes for imparting a sporicide to a surface are disclosed herein. To achieve the sporicidal efficacy of the product, a synergistic amount of an amine oxide surfactant and a mixture of oxidants is incorporated into the formulation. The operative sporicidal formulation contains a solvent, an amine oxide surfactant, a water soluble oxidant and a water insoluble oxidant. Typically, the formulation can contain about 0.05 to about 3.7 percent (by weight of the formulation) of an amine oxide surfactant, about 0.5 to about 4 percent (by weight of the formulation) of a water soluble oxidant, and about 0.1 to about 6 percent (by weight of the formulation) of a water insoluble oxidant.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: May 16, 2017
    Assignee: Kimberly-Clark Worldwide, Inc.
    Inventors: David William Koenig, Douglas Robert Hoffman, Yang Huang, Aimin He
  • Patent number: 9044527
    Abstract: Methods have been developed for incorporation of a peracid compound into or on wound application matrices, such as bandages or dressings, and other matrices which will favorably impact wound healing and help eliminate microbial infection. The peracid compound comprises a base compound that is metabolically pertinent to wound healing, the oxidized form of the base compound (a peracid), and an appropriate oxidizer, such as hydrogen peroxide. In addition, other excipients with wound healing potential, such as esters of the base compound, may be added to the peracid compound. The combination peracid-wound application matrices can be used to disinfect and heal various wound types with designed time release of the peracid compound.
    Type: Grant
    Filed: August 14, 2013
    Date of Patent: June 2, 2015
    Assignee: CHD Bioscience, Inc.
    Inventors: Edwin D. Neas, Michael K. Handley, Kevin S. Marchitto, Stephen T. Flock
  • Patent number: 9034390
    Abstract: The present invention generally relates to anti-microbial formulations and methods of their use and production. The formulations of the present invention are effective as broad spectrum anti-bacterial agents with efficacy against both Gram-negative and Gram-positive bacteria, as anti-viral agents with efficacy against both enveloped and non-enveloped viruses, and as anti-fungal agents with efficacy against both vegetative and spore forms of microorganisms and against biofilms. The present invention includes anti-microbial compositions that have at least one surfactant, at least one acid, at least one peroxide (preferably hydrogen peroxide), peracetic acid, and water. The anti-microbial Formulations of the present invention may additionally contain an organic salt. The organic salt may be a salt of the same acid that is used in the Formulation or a salt of a different acid. Methods for production and use of the inventive compositions are disclosed.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: May 19, 2015
    Assignee: BIONEUTRAL LABORATORIES CORPORATION
    Inventor: Andrew Kielbania, Jr.
  • Patent number: 8999382
    Abstract: This invention relates to a drug delivery system for administration of poorly water soluble pharmaceutically active substance, a pharmaceutical composition comprising such a drug delivery system, and a method for the preparation of such a drug delivery system. The invention also relates to a method for controlling the particle size and/or particle shape and/or particle size distribution in such a drug delivery system, and to a method for increasing the drug loading capacity of the particles. Furthermore the invention also relates to the use of such a drug delivery system for the preparation of a medicament for the treatment of cancer.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: April 7, 2015
    Assignee: Ardenia Investments, Ltd.
    Inventors: Julian Aleksov, Igor Lokot
  • Patent number: 8952063
    Abstract: The present invention relates to the field of weight management. The invention particularly relates to a method for inducing satiety. In one of its embodiments, the present invention provides a method for inducing satiety in a human or an animal comprising administering to said human or animal an effective amount of a composition comprising a lipid of which at least part is in a crystal form in the small intestine.
    Type: Grant
    Filed: May 9, 2013
    Date of Patent: February 10, 2015
    Assignee: DSM IP Assets B.V.
    Inventors: Arjen Sein, Damiet Josephina Petronella Cunera Koenders, Annika Viberg, Gerardus Johannes Franciscus Smolders, Anthonius Cornelis Van Den Vurg
  • Patent number: 8952062
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 10, 2015
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
  • Patent number: 8927604
    Abstract: Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: January 6, 2015
    Assignee: APR Applied Pharma Research s.a.
    Inventors: Giorgio Reiner, Alberto Reiner
  • Patent number: 8883855
    Abstract: Compositions and therapeutic uses of HEPES and derivatives in the treatment of pain associated with cancers and side-effects including post-chemotherapy cognitive impairment are disclosed herein. HEPES is also used to treat neurodegenerative and neurological diseases, demyelinization injuries, and side-effects and withdrawal symptoms associated with benzodiazepines, anti-depressants, and other neurological agents.
    Type: Grant
    Filed: September 17, 2010
    Date of Patent: November 11, 2014
    Assignee: North Texas Medical Associates
    Inventor: Ivan E. Danhof
  • Publication number: 20140329746
    Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
    Type: Application
    Filed: July 16, 2014
    Publication date: November 6, 2014
    Inventors: Xianqi Kong, Xinfu Wu, Abderrahim Bouzide, Isabelle Valade, David Migneault, Francine Gervais, Daniel Delorme, Benoit Bachand, Mohamed Atfani, Sophie Levesque, Bita Samim
  • Patent number: 8859616
    Abstract: The present invention provides a method for stimulating hair growth in a mammalian species or converting vellus hair or intermediate hair to terminal hair or stimulating hair follicles to increase hair growth and one or more properties selected from the group consisting of luster, sheen, brilliance, gloss, glow, shine or patina of hair associated with the follicles or increasing one or more of: length, thickness, number, and density, of eyelash hair or eyebrow hair comprising applying to the skin of a patient a composition comprising an effective amount of an EP3 agonist or an EP4 agonist prodrug or a mixture thereof. Such compositions which are used in treating the skin or scalp of a human or non-human animal may comprise an effective amount of 3, 7 or 3 and 7 thia prostanoic acid. A mixture of 3,7-dithia PGE1 and 3,7-dithia PGE1-isopropyl ester is preferred for this treatment.
    Type: Grant
    Filed: January 20, 2012
    Date of Patent: October 14, 2014
    Assignee: Allergan, Inc.
    Inventors: Jenny W. Wang, David F. Woodward
  • Patent number: 8859619
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: October 14, 2014
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
  • Patent number: 8822535
    Abstract: The present invention concerns the use of oxygen antagonists and other active compounds for inducing stasis or pre-stasis in cells, tissues, and/or organs in vivo or in an organism overall, in addition to enhancing their survivability. It includes compositions, methods, articles of manufacture and apparatuses for enhancing survivability and for achieving stasis or pre-stasis in any of these biological materials, so as to preserve and/or protect them. In specific embodiments, there are also therapeutic methods and apparatuses for organ transplantation, hyperthermia, wound healing, hemorrhagic shock, cardioplegia for bypass surgery, neurodegeneration, hypothermia, and cancer using the active compounds described.
    Type: Grant
    Filed: April 20, 2006
    Date of Patent: September 2, 2014
    Assignee: Fred Hutchinson Cancer Research Center
    Inventors: Mark B. Roth, Mike Morrison, Eric Blackstone, Dana Miller
  • Patent number: 8815948
    Abstract: An alternative method of delivery of homeopathic medicines by targeting delivery to the MALT's, especially of the intestinal tract and in high volumes.
    Type: Grant
    Filed: February 10, 2005
    Date of Patent: August 26, 2014
    Inventors: Char Tara Albert, Floyd E. Taub
  • Patent number: 8778999
    Abstract: The disclosure provides compositions and systems for topical ophthalmic application, which include an aqueous mixture of bromfenac and flowable mucoadhesive polymer, for treating inflammation and inflammatory conditions of the eye.
    Type: Grant
    Filed: March 5, 2009
    Date of Patent: July 15, 2014
    Assignee: Insite Vision Incorporated
    Inventors: Kamran Hosseini, Lyle Bowman, Erwin C. Si, Stephen Pham
  • Patent number: 8772329
    Abstract: The present invention relates to compounds from mycelium of Antrodia cinnamomea. The present invention also relates to a composition and a method for treating or prophylaxis of hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: January 28, 2008
    Date of Patent: July 8, 2014
    Assignee: Simpson Biotech Co., Ltd.
    Inventors: Chia-Chin Sheu, Masao Hattori
  • Patent number: 8759404
    Abstract: The invention discloses a stable intravenous Propofol oil-in-water emulsion composition having mixed preservatives of low toxicity that is capable of withstanding accidental contamination of bacteria and fungi. The preservative system employed comprising of monoglyceryl ester of lauric acid (Monolaurin) and a member selected from (a) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin); (b) edetate; and (c) capric acid and/or its soluble alkaline salts or its monoglyceryl ester (Monocaprin) and edetate.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: June 24, 2014
    Assignee: Bharat Serums & Vaccines Ltd.
    Inventors: Gautam Vinod Daftary, Srikanth Annappa Pai, Girish Narasimha Shanbhag, Sangeeta Hanurmesh Rivankar
  • Patent number: 8741886
    Abstract: The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid ? toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.
    Type: Grant
    Filed: December 6, 2012
    Date of Patent: June 3, 2014
    Assignee: Pharnext
    Inventors: Daniel Cohen, Ilya Chumakov, Serguei Nabirochkin, Emmanuel Vial, Mickael Guedj
  • Patent number: 8729128
    Abstract: Lipoxin A4 and its analogs have been discovered to promote the cell proliferation of cornea endothelial cells, and thus promote the proper functioning of the labile tissue layer of cornea endothelial cells. These lipoxin compounds can be administered alone or in combination with other known compounds as a solution that can be topically administered to decrease the swelling of the cornea or maintain the clarity of the cornea. Lipoxin A4 or its analogs can also be combined with other known nutritive compounds to form a solution for storage of a cornea prior to transplantation.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: May 20, 2014
    Assignee: Board of Supervisors of Louisiana State University And Agricultural and Mechanical College
    Inventors: Nicolas G. Bazan, Jiu-Cheng He, Haydee E. P. Bazan
  • Publication number: 20140107027
    Abstract: Methods, compounds, pharmaceutical compositions and kits are described for treating or preventing amyloid-related disease.
    Type: Application
    Filed: December 18, 2013
    Publication date: April 17, 2014
    Applicant: BHI LIMITED PARTNERSHIP
    Inventors: Xianqi Kong, David Migneault, Isabelle Valade, Xinfu Wu, Francine Gervais
  • Patent number: 8673975
    Abstract: Compounds of formula (Ia): wherein R1, R2, R3, R4a, R4b, R5, and R6 are defined herein, as well as other indene derivatives are disclosed herein. Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: March 18, 2014
    Assignee: Aquinox Pharmaceuticals Inc.
    Inventors: Jeffery R. Raymond, Kang Han, Yuanlin Zhou, Yuehua He, Bradley Noren, James Gee Ken Yee
  • Patent number: 8642635
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: February 4, 2014
    Assignee: Novartis AG
    Inventors: Yuki Iwaki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi
  • Patent number: 8618167
    Abstract: The present invention provides for methods of treating cognitive deficits resulting from interruption of blood supply and/or oxygen deficit by administering a therapeutically effective dose of a sulfonyl fluoride, such as methanesulfonyl fluoride and ethanesulfonyl fluoride. The underlying cause of the or oxygen deficit can be from stroke, trauma, carbon monoxide poisoning, and other poisonings. This method also includes co-administering with sulfonyl fluoride with a therapeutically effective dose of a second agent.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: December 31, 2013
    Assignee: Board of Regents, The University of Texas System
    Inventors: Cesario V. Borlongan, Donald E. Moss, Isabel C. Sumaya
  • Patent number: 8609641
    Abstract: The invention relates to a medicament containing (S)-2-N-propylamino-5-hydroxytetralin, the salts or prodrugs thereof. As a D3 agonist, (S)-2-N-propylamino-5-hydroxytetralin is suitable particularly for the treatment of dopa-sensitive movement disorders.
    Type: Grant
    Filed: December 13, 2004
    Date of Patent: December 17, 2013
    Assignee: UCB Pharma GmbH
    Inventors: Dieter Scheller, Klaus Hansen
  • Publication number: 20130310455
    Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Application
    Filed: May 9, 2013
    Publication date: November 21, 2013
    Applicant: Synchroneuron Inc.
    Inventor: Synchroneuron Inc.
  • Publication number: 20130310456
    Abstract: Embodiments disclosed herein generally relate to acamprosate formulations, methods of use of the formulations, to methods of using the formulations in combination with at least one other medication, and to combination products and compositions comprising the formulations and at least one other medication, such as neuroleptic (antipsychotic) and/or antidepressant drugs.
    Type: Application
    Filed: May 9, 2013
    Publication date: November 21, 2013
    Applicant: Synchroneuron Inc.
    Inventor: Synchroneuron Inc.
  • Patent number: 8586633
    Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
    Type: Grant
    Filed: March 14, 2012
    Date of Patent: November 19, 2013
    Assignee: Omeros Corporation
    Inventors: Gregory A. Demopulos, Pamela Pierce Palmer, Jeffrey M. Herz
  • Patent number: 8580853
    Abstract: A soluble aspirin composition, comprising: (i) granules including aspirin, heat-treated bicarbonate salt, pharmaceutically-acceptable resin and surfactant, in mixture with: (ii) crystalline particles of pharmaceutically-acceptable acid; and (iii) crystalline particles of heat-treated bicarbonate salt; wherein the soluble aspirin composition when introduced to water undergoes reaction of the crystalline particles of pharmaceutically-acceptable acid with the heat-treated bicarbonate salt and the aspirin to effect effervescing action and disintegration of the granules with conversion of the aspirin to an acetylsalicylate compound of the bicarbonate salt cation so that the composition rapidly dissolves in the water without occurrence of undissolved residue. The composition is solublizable within 30 seconds in cool to cold water to provide an effervescent analgesic solution that can be readily orally administered to an individual in need of analgesia.
    Type: Grant
    Filed: June 13, 2011
    Date of Patent: November 12, 2013
    Inventor: Howard Phykitt
  • Patent number: 8574552
    Abstract: Disclosed is a pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, said composition comprising i) an effective amount of a narcotic active ingredient, and ii) a pharmaceutically acceptable amine having a pK of about 8 or greater, wherein the molar ratio of amine:active ingredient is at least about 5:1.
    Type: Grant
    Filed: July 21, 2006
    Date of Patent: November 5, 2013
    Assignee: Alpex Pharma S.A.
    Inventors: Federico Stroppolo, Shahbaz Ardalan
  • Patent number: 8563016
    Abstract: The present invention is directed to a lamellar oil-in-glycol gel comprising (a) at least one glycol, (b) at least one fatty alcohol, (c) at least one cationic surfactant and optionally (d) at least one benefit agent, said lamellar gel capable of providing enhanced mass and promoting the permeation of the benefit agent through a keratinous substrate such as the skin, hair and fingernails, providing both deep and superficial treatment thereof.
    Type: Grant
    Filed: April 28, 2006
    Date of Patent: October 22, 2013
    Assignee: ISP Investments Inc.
    Inventors: Alexandra Bazito Agarelli, Yan Zhou, Nelson Luis Perassinoto, Maria Regina Bartuccio Raponi, Ligia Vairoletto, Liliana Calore Brenner
  • Patent number: 8541393
    Abstract: The present invention relates to inhibiting or preventing infection and protecting against patency complications after a blood catheter has been inserted in a patient comprising administering to the device a pharmaceutically effective amount of a composition comprising (A) at least one taurinamide derivative, (B) at least one compound selected from the group consisting of biologically acceptable acids and biologically acceptable salts thereof; and (C) heparin at a low concentration.
    Type: Grant
    Filed: September 2, 2011
    Date of Patent: September 24, 2013
    Assignee: ND Partners, LLC
    Inventor: Frank R. Prosl
  • Patent number: 8541472
    Abstract: Antiseptic compositions comprising at least one salt of EDTA are disclosed. These compositions have broad spectrum antimicrobial and antifungal activity and they also have anticoagulant properties. The antiseptic compositions have also demonstrated activity in penetrating and breaking down microbial slime, or biofilms. They are safe for human and medical uses and may be used as prophylactic preparations to prevent infection, or to reduce the proliferation of and/or eliminate existing or established infections.
    Type: Grant
    Filed: September 10, 2003
    Date of Patent: September 24, 2013
    Assignee: Aseptica, Inc.
    Inventors: Peter Kite, David Hatton
  • Patent number: 8530514
    Abstract: The present invention relates to the field of weight management. The invention particularly relates to a method for inducing satiety. In one of its embodiments, the present invention provides a method for inducing satiety in a human or an animal comprising administering to said human or animal an effective amount of a composition comprising a lipid of which at least part is in a crystal form in the small intestine.
    Type: Grant
    Filed: February 9, 2010
    Date of Patent: September 10, 2013
    Assignee: DSM IP Assets B.V.
    Inventors: Arjen Sein, Damiet Josephina Petronella Cunera Koenders, Annika Viberg, Gerardus Johannes Franciscus Smolders, Anthonius Cornelis Van Den Burg
  • Patent number: 8461203
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: July 13, 2011
    Date of Patent: June 11, 2013
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
  • Patent number: 8445030
    Abstract: Antiseptic compounds that act as persistent and fast acting antiseptics and disinfectants. The base of these antiseptic actions is CaF2 as the persistent part, preventing the colonization of tissue and nonliving surfaces with microorganisms through the targeted on-demand release of fluorine ions. For fighting heavy contamination and invasion of transient microbes through new application of the solution, fast acting alcohols and toxic solutions have been added in small percentage. They act fast and evaporate fast, leaving the natural protection of skin undamaged and coated with a persistent antiseptic.
    Type: Grant
    Filed: September 15, 2010
    Date of Patent: May 21, 2013
    Inventors: Fridolin Voegeli, Frank Flechsig, Thomas Flechsig
  • Publication number: 20130122120
    Abstract: The present invention provides compositions that may be an aqueous insecticide containing at least one surfactant, such as for instance, sodium lauryl sulfate, at least one preservative, such as for instance, a potassium salt or sodium chloride, a nutrient source, such as for instance a yeast, an organic acid capable of lowering the pH of the aqueous insecticide, such as for instance citric acid, a fragrance, such as for instance geranium oil, and water. The aqueous insecticide may be designed to more efficiently kill and thereby control populations of species of Cimex, such as, for instance, Cimex lectularius.
    Type: Application
    Filed: November 14, 2012
    Publication date: May 16, 2013
    Inventor: Emira Angjeli
  • Patent number: 8440719
    Abstract: Carboxylic anhydrides are highly suitable as additive for industrial materials, cosmetics, pharmaceutics and foodstuffs, in particular beverages, for protecting them against attack and/or destruction by microorganisms.
    Type: Grant
    Filed: May 25, 2012
    Date of Patent: May 14, 2013
    Assignee: LANXESS Deutschland GmbH
    Inventors: Johannes Kaulen, Erasmus Vogl, Edwin Ritzer, Manfred Hoffmann
  • Patent number: 8435971
    Abstract: The invention relates to the use of 2,5-dihydroxybenzenesulfonic acid in the production of medicaments for the treatment of angiodependent diseases. More specifically, the invention relates to the use of the aforesaid compound and, in particular, the calcium and potassium salts thereof, for the treatment of two angiodependent diseases, which present a reduction in the apoptosis, namely cancer and psoriasis. The invention also discloses the antiproliferative, antimigratory, antiangiogenic and proapoptotic capacity of said family of compounds in non-quiescent cells. In addition, the invention details the potentiating effect of said compounds on known cytostatic medicines in the treatment of tumours and, specifically, on gliomas. The invention further relates to the therapeutic efficacy of said compounds, based on the combined antiproliferative, antiangiogenic and proapaptotic capacities thereof, in the treatment of chronic psoriatic plaques.
    Type: Grant
    Filed: June 27, 2011
    Date of Patent: May 7, 2013
    Assignee: AmDerma Pharmaceuticals, LLC
    Inventors: Pedro Cuevas Sánchez, Antonio Romero Garrido, Guillermo Gimenez Gallego, Serafin Valverde Lopez, Rosa Maria Lozano Puerto
  • Publication number: 20130090314
    Abstract: Provided herein are novel solid state forms of tapentadol salts, process for their preparation, pharmaceutical compositions, and method of treating thereof. The tapentadol salts include an L-(?)-camphorsulfonate salt, a dibenzoyl-(L)-tartrate salt, a dibenzoyl-(D)-tartrate salt, a malate salt, a maleate salt, or a salicylate salt.
    Type: Application
    Filed: September 11, 2012
    Publication date: April 11, 2013
    Applicant: ACTAVIS GROUP PTC EHF
    Inventors: Mayur Devjibhai Khunt, Sandipan Prabhurao Bondge, Nitin Sharadchandra Pradhan, Depashri Vikas Ahirao
  • Patent number: 8383679
    Abstract: The present invention relates to a novel crystal form of calcium 3-acetylaminopropane-1-sulfonate, to a process for the preparation thereof, and to the use thereof in medicaments.
    Type: Grant
    Filed: August 25, 2009
    Date of Patent: February 26, 2013
    Assignee: Merck Patent Gesellschaft mit beschränkter Haftung
    Inventors: Antje Ernst, Clemens Kuehn, Matthias Bartels, Christoph Saal, Nathalie Bosc
  • Patent number: 8377978
    Abstract: The present invention provides a compound of formula I; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R6, A1, A2, X1, s and m are defined herein. The invention also relates to a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Grant
    Filed: April 18, 2012
    Date of Patent: February 19, 2013
    Assignee: Novartis AG
    Inventors: Yuki Iwaki, Toshio Kawanami, Gary Michael Ksander, Muneto Mogi
  • Publication number: 20130040916
    Abstract: The present invention relates to novel cycloalkyl-hydroxyl compounds, compositions comprising hydroxyl compounds, and methods useful for treating and preventing a variety of diseases and conditions such as, but not limited to aging, Alzheimer's Disease, cancer, cardiovascular disease, diabetic nephropathy, diabetic retinopathy, a disorder of glucose metabolism, dyslipidemia, dyslipoproteinemia, hypertension, impotence, inflammation, insulin resistance, lipid elimination in bile, obesity, oxysterol elimination in bile, pancreatitis, Parkinson's disease, a peroxisome proliferator activated receptor-associated disorder, phospholipid elimination in bile, renal disease, septicemia, Syndrome X, thrombotic disorder. Compounds and methods of the invention can also be used to modulate C reactive protein or enhance bile production in a patient.
    Type: Application
    Filed: October 12, 2012
    Publication date: February 14, 2013
    Applicant: ESPERION THERAPEUTICS, INC.
    Inventor: Esperion Therapeutics, Inc.
  • Patent number: 8324274
    Abstract: A drug delivery system (DDS) for administration of a water soluble, cationic, and amphiphilic pharmaceutically active substance (API) which DDS comprises amorphous particles of <100 nm of a poorly water soluble complex of the API with a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester, which particles are entrapped in nanoparticles formed a Na-salt of N-all-trans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester, the w/w-ratio of Na-salt of N-alltrans-retinoyl cysteic acid methyl ester and/or a Na-salt of N-13-cis-retinoyl cysteic acid methyl ester to the complex is about 0.5:1 to about 20:1. A pharmaceutical composition comprising such a DDS. Methods for preparation of such a DDS and such a pharmaceutical composition. Use of such a DDS and pharmaceutical composition for treatment of cancer.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: December 4, 2012
    Assignee: Ardenia Invesments, Ltd.
    Inventors: Julian Aleksov, Igor Lokot
  • Patent number: 8324428
    Abstract: The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds libraries thereof. The synthesis of these novel stabilized compounds involves (1) synthesizing a peptide from a selected number of natural or non-natural amino acids, wherein said peptide comprises at least two moieties capable of undergoing reaction to promote carbon-carbon bond formation; and (2) contacting said peptide with a reagent to generate at least one crosslinker and to effect stabilization of a secondary structure motif. The present invention, in a preferred embodiment, provides stabilized p53 donor helical peptides. Additionally, the present invention provides methods for disrupting the p53/MDM2 binding interaction comprising (1) providing a crosslinked stabilized ?-helical structure; and (2) contacting said crosslinked stabilized ?-helical structure with MDM2.
    Type: Grant
    Filed: June 8, 2010
    Date of Patent: December 4, 2012
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Christian E. Schafmeister
  • Patent number: 8318801
    Abstract: The invention relates to a compound represented by the following formula (I): and pharmaceutically acceptable salts, stereoisomers, enantiomers, prodrugs and solvates thereof. The compounds are useful as an agent for enhancing the neurite outgrowth and preventing or treating of diseases associated with HDAC in particular, tumor or cell proliferative diseases. In particular, the compounds of the invention can be used as an agent for anti-cancer, anti-diabetic, and anti-neurodegenerative diseases such as Alzheimer's disease, Huntington's disease, Spinocerebellar Ataxias (SCA), and human spinal muscular atrophy (SMA).
    Type: Grant
    Filed: May 24, 2011
    Date of Patent: November 27, 2012
    Assignee: Naturewise Biotech & Medicals Corporation
    Inventors: Chung-Yang Huang, Chia-Nan Chen, Wei-Jan Huang, Chia-Wei Lin, Jing-Shi Huang, Li-Ling Chi, Ai-Ling Chen, Chi-Yun Lee, Yu-Chen Huang
  • Patent number: 8299122
    Abstract: A method for stabilizing retinoic acid is provided. The method includes a step of mixing retinoic acid with a hydrophobic polymer/hydrophilic polymer adduct in the presence of an oxygen containing atmosphere to form a retinoic acid containing composition. The hydrophobic polymer/hydrophilic polymer adduct comprises a poly(vinylpyrrolidone/alkylene) polymer and a polymer comprising repeating carboxylic acid groups, hydroxyl groups, or a mixture of carboxylic acid groups and hydroxyl groups. A retinoic acid containing composition and a method of using a retinoic acid containing composition are provided.
    Type: Grant
    Filed: April 14, 2009
    Date of Patent: October 30, 2012
    Assignee: Skinvisible Pharmaceuticals, Inc.
    Inventor: James A. Roszell
  • Patent number: 8268886
    Abstract: The invention provides a novel class of reactive fluorescent agents that are based on a pyrene sulfonic acid nucleus. The agents are readily incorporated into conjugates with other species by reacting the reactive group with a group of complementary reactivity on the other species of the conjugate. Also provided are methods of using the compounds of the invention to detect and/or quantify an analyte in a sample. In an exemplary embodiment, the invention provides multi-color assays incorporating the compounds of the invention.
    Type: Grant
    Filed: May 31, 2011
    Date of Patent: September 18, 2012
    Assignee: Life Technologies Corporation
    Inventors: Richard Haugland, Wai-Yee Leung, Jixiang Liu
  • Patent number: 8263650
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gammahydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: April 13, 2012
    Date of Patent: September 11, 2012
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
  • Patent number: RE44874
    Abstract: The present invention relates to novel compounds of formula (I), to a process for their manufacture, to pharmaceutical compositions containing them, and to their use in therapy, in particular their use in the prophylaxis and treatment of respiratory diseases
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: April 29, 2014
    Assignee: Glaxo Group Limited
    Inventors: Philip Charles Box, Diane Mary Coe, Brian Edgar Looker, Panayiotis Alexandrou Procopiou